Published in
American Association for the Advancement of Science, Science Translational Medicine, 391(9), 2017
DOI: 10.1126/scitranslmed.aal2439
Links
Tools
Comment on “Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin”
Journal article published in 2017 by
Stefan Winter,
Pascale Fisel,
Anne T. Nies 
,
Arnulf Stenzl,
Matthias Schwab ,
Elke Schaeffeler,
Florian Büttner ,
Jens Bedke
,
Arnulf Stenzl,
Matthias Schwab ,
Elke Schaeffeler,
Florian Büttner ,
Jens Bedke
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
Although the combination of decitabine and platinum drugs may be promising for therapy of renal cell carcinoma, the role of OCT2 needs further investigations.